Marissa Mock

Title: Marissa Mock: Innovator in Biopharmaceuticals

Introduction

Marissa Mock is a prominent inventor based in Newbury Park, California. She has made significant contributions to the field of biopharmaceuticals, holding a total of five patents. Her work focuses on innovative treatments that target specific proteins involved in immune responses.

Latest Patents

Among her latest patents are the TIGIT and CD112R blockade. This patent provides a range of TIGIT binding proteins, CD112R binding proteins, and their combinations. It also includes compositions that comprise these binding proteins, potentially combined with PD-1 binding proteins. Furthermore, the patent outlines related conjugates, fusion proteins, nucleic acids, vectors, host cells, and kits. Additionally, it describes pharmaceutical compositions that include a TIGIT binding protein, a CD112R binding protein, or a combination thereof, along with methods for treating subjects in need of these therapies. Another notable patent involves Interleukin-21 mutein and anti-PD-1 antibody conjugates, which are designed for treating diseases. This patent also covers related conjugates, nucleic acids, vectors, host cells, and pharmaceutical compositions.

Career Highlights

Marissa Mock has established herself as a key figure in her field through her innovative research and development efforts. Her work at Amgen Inc. has allowed her to collaborate with other leading scientists and contribute to groundbreaking advancements in biopharmaceuticals.

Collaborations

Some of her notable coworkers include Zhulun Wang and Gunasekaran Kannan. Their collaborative efforts have further enhanced the impact of their research in the industry.

Conclusion

Marissa Mock's contributions to biopharmaceuticals through her patents and collaborative work highlight her role as an influential inventor. Her innovative approaches to treating diseases continue to shape the future of medical science.